JP2015500812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500812A5 JP2015500812A5 JP2014544970A JP2014544970A JP2015500812A5 JP 2015500812 A5 JP2015500812 A5 JP 2015500812A5 JP 2014544970 A JP2014544970 A JP 2014544970A JP 2014544970 A JP2014544970 A JP 2014544970A JP 2015500812 A5 JP2015500812 A5 JP 2015500812A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- acamprosate
- pharmaceutically acceptable
- acceptable salt
- tablet according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004047 acamprosate Drugs 0.000 claims 19
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229960001157 acamprosate calcium Drugs 0.000 claims 10
- 230000000561 anti-psychotic effect Effects 0.000 claims 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 7
- 229920002125 Sokalan® Polymers 0.000 claims 7
- 229960001631 carbomer Drugs 0.000 claims 7
- 229920001519 homopolymer Polymers 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 4
- 239000000164 antipsychotic agent Substances 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229960004503 metoclopramide Drugs 0.000 claims 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960005245 asenapine Drugs 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 229960002690 fluphenazine Drugs 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960000423 loxapine Drugs 0.000 claims 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 1
- 229960001432 lurasidone Drugs 0.000 claims 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 229960000762 perphenazine Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
- 229960005013 tiotixene Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566550P | 2011-12-02 | 2011-12-02 | |
| US61/566,550 | 2011-12-02 | ||
| US201261649137P | 2012-05-18 | 2012-05-18 | |
| US61/649,137 | 2012-05-18 | ||
| PCT/US2012/067507 WO2013082573A1 (en) | 2011-12-02 | 2012-12-02 | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500812A JP2015500812A (ja) | 2015-01-08 |
| JP2015500812A5 true JP2015500812A5 (OSRAM) | 2016-01-28 |
| JP6407720B2 JP6407720B2 (ja) | 2018-10-17 |
Family
ID=48536156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544970A Active JP6407720B2 (ja) | 2011-12-02 | 2012-12-02 | アカンプロサート製剤 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2785337B1 (OSRAM) |
| JP (1) | JP6407720B2 (OSRAM) |
| KR (1) | KR102055859B1 (OSRAM) |
| CN (1) | CN104379138B (OSRAM) |
| AU (1) | AU2012345659B2 (OSRAM) |
| BR (1) | BR112014013374B1 (OSRAM) |
| CA (1) | CA2863265C (OSRAM) |
| HK (2) | HK1199841A1 (OSRAM) |
| IL (1) | IL232935B (OSRAM) |
| MX (1) | MX375183B (OSRAM) |
| RU (1) | RU2671399C2 (OSRAM) |
| SG (1) | SG11201403785UA (OSRAM) |
| WO (1) | WO2013082573A1 (OSRAM) |
| ZA (1) | ZA201404826B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
| WO2020206107A1 (en) * | 2019-04-03 | 2020-10-08 | Synchroneuron Inc. | Formulations |
| BR112022004670A2 (pt) * | 2019-10-11 | 2022-06-07 | Hoffmann La Roche | Dispositivo de computação e método implementado por computador |
| WO2022174269A1 (en) * | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU765522B2 (en) * | 1998-01-13 | 2003-09-18 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| MXPA04010956A (es) * | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
| RU2284814C1 (ru) * | 2005-04-08 | 2006-10-10 | Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" | Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| EP2099430A2 (en) * | 2006-12-07 | 2009-09-16 | Schering Corporation | Ph sensitive matrix formulation |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| WO2011102506A1 (ja) * | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | 経口用徐放性固形製剤 |
| CN101987081B (zh) * | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| CA2850468C (en) * | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
-
2012
- 2012-12-02 SG SG11201403785UA patent/SG11201403785UA/en unknown
- 2012-12-02 HK HK15100399.0A patent/HK1199841A1/xx unknown
- 2012-12-02 JP JP2014544970A patent/JP6407720B2/ja active Active
- 2012-12-02 KR KR1020147018413A patent/KR102055859B1/ko active Active
- 2012-12-02 AU AU2012345659A patent/AU2012345659B2/en active Active
- 2012-12-02 EP EP12853036.7A patent/EP2785337B1/en active Active
- 2012-12-02 CA CA2863265A patent/CA2863265C/en active Active
- 2012-12-02 BR BR112014013374-3A patent/BR112014013374B1/pt not_active IP Right Cessation
- 2012-12-02 CN CN201280068973.8A patent/CN104379138B/zh active Active
- 2012-12-02 MX MX2014006574A patent/MX375183B/es active IP Right Grant
- 2012-12-02 RU RU2014126879A patent/RU2671399C2/ru active IP Right Revival
- 2012-12-02 WO PCT/US2012/067507 patent/WO2013082573A1/en not_active Ceased
- 2012-12-02 HK HK15108166.4A patent/HK1207563A1/xx unknown
-
2014
- 2014-06-02 IL IL232935A patent/IL232935B/en active IP Right Grant
- 2014-06-30 ZA ZA2014/04826A patent/ZA201404826B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2010510286A5 (OSRAM) | ||
| JP2015500812A5 (OSRAM) | ||
| Kumar et al. | Sustained release matrix type drug delivery system: An overview | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| WO2014144661A4 (en) | Rapidly dispersible dosage form of topiramate | |
| WO2010020856A3 (en) | Rate modulated delivery of drugs from a composite delivery system | |
| WO2014106116A8 (en) | Therapeutic compositions comprising antibodies | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| AR084865A1 (es) | Preparacion de desintegracion rapida, comprimido dispersable por via oral | |
| JP2012107063A5 (OSRAM) | ||
| PE20081464A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| CN102188756A (zh) | 一种含药缓释降解骨支架的制备方法 | |
| JP2016530238A5 (OSRAM) | ||
| Aslam et al. | Techniques and polymers used to design Gastroretentive drug delivery systems–a review | |
| JP2015120758A5 (OSRAM) | ||
| CN105025882B (zh) | 熔融挤出而成的控释药物组合物及包含其的口服制剂 | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| CN102860895A (zh) | 带缓释支架的子宫托 | |
| TN2012000255A1 (en) | Sustained-release formulation | |
| RU2016127361A (ru) | Гастроретентивные фармацевтические композиции для перорального введения | |
| WO2011018246A3 (en) | Controlled release paliperidone composition | |
| JP2019514977A5 (OSRAM) | ||
| RU2017134794A (ru) | Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства | |
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением |